Marye Gleva is a Cardiology physician affiliated with Washington University in St. Louis. OpenAlex indexes 99 publications with 3,669 citations (h-index 24); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4921 Parkview Pl
Div Im Cardiology, Ste 8b
Saint Louis, MO 631101032
Telephone
314-362-1291Registry record last updated 17 Apr 2025.
Clinical trials
- ASSURE WCD Clinical Evaluation - Conversion Efficacy Study
Sponsor: Kestra Medical Technologies, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BIOTRONIK INC.Program year20251 payment
- CARDIVA MEDICAL, INC.Program year20251 payment
- Abbott LaboratoriesProgram year202416 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
66.7%Beta blocker33.1%Metoprolol Succinate41%Sotalol32%Metoprolol Tartrate18%Nebivolol Hcl4%Atenolol3%Carvedilol2%Part D<11 patientsAntiarrhythmic22.5%Amiodarone Hcl55%Dofetilide36%Mexiletine Hcl10%Part D<11 patients+ 7 more classes in this area
Blood & clotting
32.6%Factor Xa inhibitor30.4%Eliquis86%Xarelto14%Part D≥69 patientsVitamin K antagonist2.2%Warfarin Sodium100%Part D<11 patientsMetabolism & gastrointestinal
0.7%SGLT2 inhibitor0.7%Farxiga100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Stereotactic Arrhythmia Radiation Therapy Versus Repeat Catheter Ablation for Refractory Ventricular Tachycardia: 3-Year Safety and Efficacy Outcomes
International Journal of Radiation Oncology*Biology*Physics
2025 - Presentation and Prognosis of Excessive Asymptomatic Atrial Ectopy in Children and Adolescents With Structurally and Functionally Normal Hearts
The American Journal of Cardiology
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Timothy Ley, MD
Washington University in St. Louis
David Gutmann, MD
Washington University in St. Louis
Randall Bateman, MD
Washington University in St. Louis
Victoria Fraser, MD
Washington University in St. Louis
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”